AP1891A - HIV immunogenic compositions and methods. - Google Patents

HIV immunogenic compositions and methods.

Info

Publication number
AP1891A
AP1891A APAP/P/2001/002300A AP2001002300A AP1891A AP 1891 A AP1891 A AP 1891A AP 2001002300 A AP2001002300 A AP 2001002300A AP 1891 A AP1891 A AP 1891A
Authority
AP
ARIPO
Prior art keywords
mammal
immunogenic compositions
hiv
iss
adjuvant
Prior art date
Application number
APAP/P/2001/002300A
Other languages
English (en)
Other versions
AP2001002300A0 (en
Inventor
Ronald B Moss
Original Assignee
The Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Immune Response Corp filed Critical The Immune Response Corp
Publication of AP2001002300A0 publication Critical patent/AP2001002300A0/xx
Application granted granted Critical
Publication of AP1891A publication Critical patent/AP1891A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/2001/002300A 1999-05-06 2000-05-05 HIV immunogenic compositions and methods. AP1891A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25
PCT/US2000/012495 WO2000067787A2 (fr) 1999-05-06 2000-05-05 Compositions et procedes immunogenes anti-vih

Publications (2)

Publication Number Publication Date
AP2001002300A0 AP2001002300A0 (en) 2001-12-31
AP1891A true AP1891A (en) 2008-09-23

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002300A AP1891A (en) 1999-05-06 2000-05-05 HIV immunogenic compositions and methods.

Country Status (8)

Country Link
EP (1) EP1176978A2 (fr)
AP (1) AP1891A (fr)
AU (1) AU4992900A (fr)
BR (1) BR0010323A (fr)
CA (1) CA2372960C (fr)
CR (1) CR6491A (fr)
OA (1) OA11937A (fr)
WO (1) WO2000067787A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
CN1293192C (zh) 2000-12-27 2007-01-03 戴纳瓦克斯技术公司 免疫调节性多核苷酸及其使用方法
WO2002058726A1 (fr) * 2001-01-26 2002-08-01 The Immune Response Corporation Procede de traitement d'un individu infecte par le vih en associant l'immunisation a une interruption structuree du traitement antiretroviral
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
DK1446162T3 (da) 2001-08-17 2008-12-08 Coley Pharm Gmbh Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
SG167667A1 (en) * 2002-07-03 2011-01-28 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004058179A2 (fr) 2002-12-23 2004-07-15 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs en sequences et leurs methodes d'utilisation
BRPI0413906A (pt) * 2003-08-28 2006-10-24 Immune Response Corp Inc composições imunogênicas de hiv, kit e métodos relacionados
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
WO2010051820A1 (fr) * 2008-11-10 2010-05-14 Aarhus Universitet Vaccination contre multiplexée par la cytokine
MX350198B (es) 2011-07-06 2017-08-30 Novartis Ag Emulsiones aceite en agua que contienen acidos nucleicos.
JP6120839B2 (ja) 2011-07-06 2017-04-26 ノバルティス アーゲー カチオン性水中油型エマルジョン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (fr) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1005368E (pt) * 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (fr) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Vaccine, GB, Butterworth Scientific, Guildford, Vol. 16, No. 7, 1 *
Vaccine, Vol. 18, No. 11-12, 01/2000 *

Also Published As

Publication number Publication date
AP2001002300A0 (en) 2001-12-31
OA11937A (en) 2006-04-12
EP1176978A2 (fr) 2002-02-06
CA2372960A1 (fr) 2000-11-16
WO2000067787A2 (fr) 2000-11-16
CA2372960C (fr) 2006-03-28
WO2000067787A3 (fr) 2001-04-26
BR0010323A (pt) 2002-01-08
CR6491A (es) 2005-05-31
AU4992900A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
AP1891A (en) HIV immunogenic compositions and methods.
ES2272012T5 (es) Proteinas de fusion que comprenden las proteinas tat y/o nef del vih-1.
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
HK1044484B (zh) 含皂草苷和免疫刺激寡核苷酸的佐劑組合物
TW200621806A (en) Vaccine
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
HK1038507A1 (en) Influenza virus vaccine composition
ZA200500073B (en) Iscom preparation and use thereof.
WO2000057917A3 (fr) Compositions d'adjuvant et methodes permettant d'accentuer les reponses immunitaires a des vaccins a base de polynucleotides
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
WO2004007679A3 (fr) Potentialisation des cellules dendritiques
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2005013918A3 (fr) Compositions, methodes et kits de vaccins a base de sous-unite de poxvirus
NZ525752A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
WO2003082183A3 (fr) Vaccins contre streptococcus pneumoniae a base proteique
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2002036790A3 (fr) Vecteur de virus grippal destine a l'infection de cellules dendritiques
MA32821B1 (fr) Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)
WO2005021726A3 (fr) Compositions immunogenes contre le vih et methodes correspondantes
EP0830456A4 (fr) MOLECULE ISOLEE D'ACIDE NUCLEIQUE DE PROTEINE B REGULEE PAR Fe (FrpB) ET VACCIN UTILISANT CETTE MOLECULE
TW200502245A (en) Vaccine
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof